FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely ophthalmology, and may be used for treating, stabilising and/or preventing macular degeneration. The therapy involves introduction of a therapeutically effective amount of the C5 agent in a combination with a VEGF agent in an individual in need thereof. The C5 agent is bound with C5 complement and has the sequence SEQ ID N0:4 or SEQ ID N0:67.
EFFECT: invention provides an additive or synergetic effect ensured by the combination that leads to improved visual acuity especially in the patients suffering wet age-related macular degeneration (AMD) as compared with the VEGF monotherapy.
67 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APTAMERIC THERAPEUTIC AGENTS APPLICABLE FOR TREATING COMPLEMENT-RELATED DISORDERS | 2006 |
|
RU2406507C2 |
| NEW CONNECTING C5a NUCLEIC ACIDS | 2013 |
|
RU2645261C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF DEGOS DISEASE | 2011 |
|
RU2570390C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| C3b ANTIBODIES AND METHODS FOR PREVENTION AND TREATMENT OF COMPLEMENT-RELATED DISORDERS | 2008 |
|
RU2473563C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
| SDF-1 BINDING NUCLEIC ACIDS | 2007 |
|
RU2590709C2 |
| GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2577726C2 |
| GENETIC POLYMORPHISMS ACCOMPANYING AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2546008C2 |
